MedTrace Logo

The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

NCT05762458 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2023-03-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

Ammoxetine

Ammoxetine hydrochloride enteric-coated tablets

DRUG

Placebo

placebo to Ammoxetine.

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2024-05-15
Completion
2024-10-15

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05762458 on ClinicalTrials.gov